INTRODUCTION


AIM

- To present the updated result on the safety and efficacy of zevor-cel from Phase 1 study with a longer follow up.

METHOD

- This was a single-arm, open-label study conducted at five sites in China. Patients with RRMM who had UHFHLYHG • SULRU UHJLPHQV LQFOXGLQJ D SURWHDVRPH inhibitor and an immunomodulatory agent with an eastern cooperative oncology group (ECOG) score of 0 or 1 were enrolled. Zevor-cel was administered as a single infusion of 100×10^6 or 150×10^6 CAR+ T cells.
- The primary endpoints were safety and the secondary endpoints included efficacy and pharmacokinetics.
- Response was assessed per the international myeloma working group (IMWG) 2016 criteria.

- In this open-label, multi-center, phase 1 clinical study in patients with RRMM, with approximately 5 years of follow-up, zevor-cel reaffirms the results with a manageable safety profile and compelling efficacy in



- Between July 23, 2019 and July 10, 2020, 14 patients with a median age of 54 years received a single infusion of zevor-cel (100×10^6 CAR+ T cells in 3 patients, 150×10^6 CAR+ T cells in 11 patients).
- As of February 22, 2025, the median follow-up duration was 53.3 months (range:14.8, 63.5).
- Within the subjects achieving CR/sCR, MRD negativity (<10 -2483K3.9"( )p3'8-4 'ID„p <014>3.17 <014005A> Tf 0 T002 Tc 0.002 Tw-1. [<0EB[(up)-3